Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
about
ATM, ATR and DNA-PKcs expressions correlate to adverse clinical outcomes in epithelial ovarian cancersPathway-specific engineered mouse allograft models functionally recapitulate human serous epithelial ovarian cancerPARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesisLoss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib.Mechanisms and Targets Involved in Dissemination of Ovarian Cancer.Is there an epigenetic component underlying the resistance of triple-negative breast cancers to parp inhibitors?Ovarian cancer: can proteomics give new insights for therapy and diagnosis?Toll-like receptor 8: augmentation of innate immunity in platinum resistant ovarian carcinomaTriapine potentiates platinum-based combination therapy by disruption of homologous recombination repair.Patient selection and targeted treatment in the management of platinum-resistant ovarian cancer.(18)F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer.Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors.Ovarian cancer-associated mutations disable catalytic activity of CDK12, a kinase that promotes homologous recombination repair and resistance to cisplatin and poly(ADP-ribose) polymerase inhibitors.Resistance to PARP-Inhibitors in Cancer Therapy.The molecular genetics of hereditary and sporadic ovarian cancer: implications for the future.Safety evaluation of olaparib for treating ovarian cancer.APE1 overexpression promotes the progression of ovarian cancer and serves as a potential therapeutic target.Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer.Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature.Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers
P2860
Q28271111-F43F1D2D-C4C9-4B81-9C11-18BAED79F6FDQ28538059-3D4ED569-EA77-4428-8D7B-B532D47FB3F1Q34434937-A23407E1-8682-4A0E-8AF3-403BA90FB8BDQ35833060-FD3C64B7-30B2-4B4B-BE21-EE7757FB929CQ36087979-D67B76E6-FFC8-462B-90A2-56E233002649Q36180735-8B6F48D3-EB61-4BD4-86C6-24CABC35985DQ36490203-4B0AB066-A145-4301-8ECB-30D5C0F8E729Q36820579-FC5346E3-23FE-4D3E-A345-1CCE33E3A30CQ36884862-6472AAF7-DD57-4D89-B355-9B99621C0A85Q37174956-C0BB0FC9-32E6-44CF-BD29-43815AC09ABFQ37220528-A6EDA8CC-135F-4AB6-A234-139E3315BE75Q37236032-0CCEB14C-7AFD-4985-9E75-E0214E70890EQ37656353-66420819-37F1-4248-A2DD-5D13C0C97376Q37691597-C059F01F-BCE4-4CD4-B47F-03F1C95769F9Q38085600-95F88A48-14D5-4F4D-9855-25087BF4785CQ38282823-39B7B77C-4E5E-471F-8A2C-89E8DB20CA1EQ38519719-A63F143E-F7CA-4187-99EE-702DE55D2A7AQ38734522-D6B2CC7F-C65F-4F6A-B8F2-EC0D7D99BBC8Q38954348-95BFC66B-F8DA-4CB0-AC58-C96A2BA4785AQ48110323-21C8323A-9DC2-41CC-8F50-483DEDC74268Q48110433-4867C2BB-219F-417E-9C6E-380D1A4CC6D1Q58795530-B82D5349-91B6-424F-A8CD-1E8E2F12D4C4
P2860
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Poly (ADP-ribose) polymerase i ...... for epithelial ovarian cancer.
@en
type
label
Poly (ADP-ribose) polymerase i ...... for epithelial ovarian cancer.
@en
prefLabel
Poly (ADP-ribose) polymerase i ...... for epithelial ovarian cancer.
@en
P2093
P2860
P1476
Poly (ADP-ribose) polymerase i ...... for epithelial ovarian cancer.
@en
P2093
Alan C Sartorelli
Elena S Ratner
Z Ping Lin
P2860
P304
P356
10.1097/CCO.0B013E3283564230
P577
2012-09-01T00:00:00Z